Cell & Gene Therapy: Curing the 'Incurable'

Published on January 19, 2023

Until recently, there had been multiple breakthrough therapies for rare diseases but few cures. Now, advancements in CGT (cell and gene therapies) create possibilities to cure the “incurable”. Yet behind the scenes, each wave of innovation poses challenges for manufacturers, healthcare systems, and payers. We interviewed pharmaceutical Pricing & Market Access experts, Dirk Kars and Christian Schuler, to find out how P&MA hurdles can be overcome, facilitating better access to future cell and gene therapies.

Dirk, Christian, Simon-Kucher has supported pharmaceutical companies in monetizing over 20 gene and cell therapy products around the globe. What is different for these innovations compared to “normal” drugs?

Christian: Cell and gene therapies are disease-modifying, typically, one-shot therapies that treat genetic defects, and in most cases carry very high value for patients and their healthcare systems. So…

Continue reading on website
Other news

Consolidation of Sub-National Commissioning in the UK

January 19, 2023
UK healthcare is transitioning from Clinical Commissioning Groups to the Integrated Care System. This change will have a significant ripple effect on a sub-national level. Industry experts Sara Jacobs, Graham Tatham and Rachel Rowbottom explain how this will affect manufacturers and what steps they need to take for continued growth.Special thanks to Sam Calderwood for contributing to this article.

A Long Way From Sales Excellence: Mystery Shopping Study Shows BPO’s Huge Potential

January 19, 2023
Companies in the Business Process Outsourcing (BPO) industry face tough competition nowadays. To stay ahead of the curve, an excellent sales organization is needed. How do BPO companies perform in this respect? We conducted a mystery shopping study to find out.In today’s economic environment, companies need to be more flexible and agile as ever. Combined with the fact that only few industries need